Links


English version

Publikationen Marcus Groettrup

  1. Pircher H, Rabaï N, Groettrup M, Grégoire C, Speiser DE, Happ MP, Palmer E, Zinkernagel RM, Hengartner H, Malissen B. 1992. Preferential positive selection of Vα2+CD8+ T cells in mouse strains expressing both H-2k and T cell receptor Vαa haplotypes: determination with a Vα2-specific monoclonal antibody. Eur J Immunol 22:399-404.
  2. Groettrup M, Baron A, Griffiths G, Palacios R, von Boehmer H. 1992. T cell receptor (TCR) β chain homodimers on the surface of immature but not mature α,γ,δ chain deficient T cell lines. EMBO J 11:2735-2746.
  3. Groettrup M, von Boehmer H. 1993. T cell receptor β chain dimers on immature thymocytes from normal mice. Eur J Immunol 23:1393-1396.
  4. Bernard O, Groettrup M, Mugneret F, Berger R, Azogui O. 1993. Molecular analysis of T cell receptor transcripts in a human T cell leukemia bearing a t(1;14) and an inv(7); cell surface expression of a TCR-β chain in the absence of α chain. Leukemia 7:1645-1653.
  5. Groettrup M, Ungewiss K, Azogui O, Palacios R, Owen MJ, Hayday AC, von Boehmer H. 1993. A novel disulfide-linked heterodimer on pre - T cells consists of the T cell receptor β chain and a 33 kD glycoprotein. Cell 75:283-294.
  6. Groettrup M, von Boehmer H. 1993. A role for a pre - T cell receptor in T - cell development. Immunol Today 14:610-614.
  7. Saint-Ruf C, Ungewiss K, Groettrup M, Bruno L, Fehling HJ, von Boehmer H. 1994. Analysis and expression of a cloned pre - T cell receptor gene. Science 266:1208-1212.
  8. Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszinowski UH, Kloetzel PM. 1995. The interferon-γ-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro. J Biol Chem 270:23808-23815.
  9. Kuckelkorn U, Frentzel S, Kraft R, Kostka S, Groettrup M, Kloetzel PM. 1995. Incorporation of major histocompatibility complex - encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-γ. Eur J Immunol 25:2605-2611.
  10. Groettrup M, Kraft R, Kostka S, Standera S, Stohwasser R, Kloetzel PM. 1996. A third interferon-γ-induced subunit exchange in the 20S proteasome. Eur J Immunol 26:863-869.
  11. Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, Rammensee HG, Koszinowski UH, Kloetzel PM. 1996. A role for the proteasome regulator PA28α in antigen presentation. Nature 381:166-168.
  12. Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel PM, Ehrlich R. 1996. LMP-associated proteolytic activities and TAP-dependent transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med 183:499-514.
  13. Groettrup M, Soza A, Kuckelkorn U, Kloetzel PM. 1996. Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today 17:429-435.
  14. Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrup M, Sijts A, Mengedé E, Kloetzel PM, Neefjes J, Koszinowski UH, Melief C. 1996. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 5:115-124.
  15. Dick TP, Ruppert T, Groettrup M, Kloetzel PM, Kuehn L, Koszinowski UH, Stevanovic S, Schild H, Rammensee H. 1996. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86:253-262.
  16. Stohwasser R, Standera S, Peters I, Kloetzel PM, Groettrup M. 1997. Molecular cloning of the mouse proteasome subunts MC14 and MECL-1: reciprocally regulated tissue expression of interferon-γ-modulated proteasome subunits. Eur J Immunol 27:1182-1187.
  17. Soza A, Groettrup M, Henklein P, Tanaka K, Kloetzel PM. 1997. Expression and subcellular localization of mouse 20S proteasome PA28 regulator. FEBS Lett 406:27-34.
  18. Groettrup M, Standera S, Stohwasser R, Kloetzel PM. 1997. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci USA 94:8970-8975.
  19. Schmidtke G, Eggers M, Ruppert T, Groettrup M, Koszinowski UH, Kloetzel PM. 1998. Inactivation of a defined active site in the mouse 20S proteasome complex enhances MHC class I antigen presentation of a mouse cytomegalovirus protein. J Exp Med 187:1641-1646.
  20. Gallimore A, Schwarz K, van den Broek M, Hengartner H, Groettrup M. 1998. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Mol Immunol 35:581-591.
  21. André P, Groettrup M, Klenerman P, de Giuli R, Booth Jr. BL, Cerundolo V, Bonneville M, Jotereau F, Zinkernagel RM, Lotteau V. 1998. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 95:13120-13124.
  22. Groettrup M, Schmidtke G. 1999. Selective proteasome inhibitors: modulators of antigen presentation? Drug Discovery today 4:63-71.
  23. Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, Groettrup M. 1999. Dendritic cells upregulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol 29:4030-4036.
  24. Raasi S, Schmidtke G, de Giuli R, Groettrup M. 1999. A ubiquitin-like protein which is synergistically inducible by interferon-γ and tumor necrosis factor-α. Eur J Immunol 29:4037-4042.
  25. Groettrup M, Schmidtke G. 1999. Intracellular processing of viral and tumour antigens by proteasomes. Schweiz Med Wochenschr 129:1660-1665.
  26. Schmidtke G, Holzhütter HG, Bogyo M, Kairies N, Groll M, de Giuli R, Groettrup M. 1999. How an inhibitor of the HIV-1 protease modulates proteasome activity. J Biol Chem 274:35734-35740.
  27. Schwarz K, van den Broek M, de Giuli R, Seelentag WW, Shastri N, Groettrup M. 2000. The use of LCMV-specific T cell hybridomas for the quantitative analysis of MHC class I restricted antigen presentation. J Immunol Methods 237:199-202.
  28. Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Broek M, Kim KB, Crews CM, Kraft R, Groettrup M. 2000. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or downregulate antigen presentation at nontoxic doses. J Immunol 164:6147-6157.
  29. Schmidtke G, Emch S, Groettrup M, Holzhütter HG. 2000. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20S proteasome. J Biol Chem 275:22056-22063.
  30. Schwarz K, van den Broek M, Kostka S, Kraft R, Soza A, Schmidtke G, Kloetzel PM, Groettrup M. 2000. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1 but not PA28α/β enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J Immunol 165:768-778.
  31. Dannull J, Diener PA, Prickler L, Fürstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M. 2000. Prostate stem cell antigen (PSCA) is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 60:5522-5528.
  32. Dannull J, Cerny T, Ackermann DK, Groettrup M. 2000. Current status of dendritic cell-based tumor vaccination. Onkologie 23:544-551.
  33. Schwarz K, Eggers M, Soza A, Koszinowski UH, Kloetzel PM, Groettrup M. 2000. The proteasome regulator PA28α/β can enhance antigen presentation without affecting 20S proteasome subunit composition. Eur J Immunol 30:3672-3679.
  34. Limmer A, Ohl J, Kurts C, Ljungren HG, Reiss Y, Groettrup M, Momburg F, Arnold B, Knolle PA. 2000. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nature Med 6:1348-1354.
  35. Groettrup M, Khan S, Schwarz K, Schmidtke G. 2001. Interferon-γ inducible exchanges of 20S proteasome active site subunits: Why? Biochimie 83:367-372.
  36. Moradpour D, Grabscheid B, Kammer AR, Schmidtke G, Groettrup M, Blum HE, Cerny A. 2001. Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. Hepatology 33:1282-1287.
  37. Raasi S, Schmidtke G, Groettrup M. 2001. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem 276:35334-35343.
  38. Macagno A, Kuehn L, de Giuli R, Groettrup M. 2001. Pronounced upregulation of the PA28α/β proteasome regulator but little increase in the steady state content of immunoproteasomes during dendritic cell maturation. Eur J Immunol 31:3271-3280.
  39. Khan S, de Giuli R, Schmidtke G, Bruns M, Buchmeier M, van den Broek M, Groettrup M. 2001. Cutting Edge: Neosynthesis is required for the presentation of a T cell epitope from a long lived viral protein. J Immunol 167:4801-4804.
  40. Khan S, van den Broek M, Schwarz K, de Giuli R, Diener PA, Groettrup M. 2001. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol 167:6859-6868.
  41. Groettrup M, van den Broek M, Schwarz K, Macagno A, Khan S, de Giuli R, Schmidtke G. 2001. Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol 21:339-359.
  42. Scandella E, Men Y, Gillessen S, Förster R, Groettrup M. 2002. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100:1354-1361.
  43. Audran R, Peter K, Dannull J, Men Y, Groettrup M, Gander B, Corradin G. 2002. Micro-encapsulation of peptides prolongs their presentation to cytotoxic T cells by antigen presenting cells in vitro. Vaccine 21:1250-1255.
  44. Gillessen S, Groettrup M, Cerny T. 2003. Proteasomes, a new target for cancer therapy. Onkologie 25:534-539.
  45. Froeschke M, Basler M, Groettrup M, Dobberstein B. 2003. Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J Biol Chem 278:41914-41920.
  46. Khan S, Zimmermann A, Basler M, Groettrup M, Hengel H. 2004. A cytomegaloviral inhibitor of IFN-gamma signaling controls immunoproteasome assembly. J Virol 78:1831-1842.
  47. Scandella E, Men Y, Gillessen S, Prikler L, Groettrup M. 2004. CCL19/CCL21 triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 103:1595-1601.
  48. Hipp MS, Raasi S, Groettrup M, Schmidtke G. 2004. NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation. J Biol Chem 279:16503-16510.
  49. Waeckerle-Men Y, Scandella E, Uetz-von Allmen E, Ludewig B, Gillessen S, Merkle HP, Gander B, Groettrup M. 2004. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable PLGA microspheres for DC-vaccination. J Immunol Methods 287:109-124.
  50. Basler M, Youhnovski N, van den Broek M, Przybylski M, Groettrup M. 2004. Immunoproteasomes downregulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol 173:3925-3934.
  51. Waeckerle-Men Y, Groettrup M. 2004. PLGA microspheres for an improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Delivery Rev 57:475-482.
  52. Groettrup M, de Giuli R, Schmidtke G. 2004. Effects of the HIV-1 protease inhibitor Ritonavir on proteasome activity and antigen presentation. In Adams, J.: Proteasome inhibitors in cancer therapy Humana Press, Totowa, NJ., in the press
  53. Waeckerle-Men Y, Gander B, Groettrup M. 2005. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 109:35-46.
  54. Waeckerle-Men Y, Uetz-von Allmen E, von Moos R, Classon BJ, Scandella E, Schmid HP, Ludewig B, Groettrup M, Gillessen S. 2005. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T- cell stimulation. Prostate 64(4):323-331.
  55. Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G. 2005. FAT10 - a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 25:3483-3491.
  56. Basta S, Stoessel R, Basler M, van den Broek M, Groettrup M. 2005. Cross-Presentation of the long-lived Lymphocytic Choriomeningitis Virus Nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 175:796-805.
  57. Alvarez G, De Giuli R, Kolb C, Groettrup M. 2005. A rapid method to determine the activities of proteasomes and immunoproteasomes. MACS & more 9:4-7.
  58. Waeckerle-Men Y, Uetz-von Allmen E, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M. 2006. Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 24(11):1847-1857.
  59. Legler DF, Krause P, Scandella E, Singer E, Groettrup M. 2006. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 176:966-973.
  60. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Boehme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. 2006. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55(12):1524-33. Epub 2006 Apr 13
  61. Schmidtke G, Kalveram B, Weber E, Bochtler P, Lukasiak S, Hipp MS, Groettrup M. 2006. The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10. J Biol Chem 281:20045-20054.
  62. Basler M, Moebius J, Elenich L, Groettrup M, Groettrup M, Monaco JJ. 2006. An altered T cell repertoire in MECL-1-deficient mice. J Immunol 176:6665-6672.
  63. Otero C, Groettrup M, Legler D. 2006. Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol 177:2314-2323.
  64. Fischer S, Uetz-von Allmen E, Waeckerle-Men Y, Groettrup M, Merkle HP, Gander B. 2007. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 28:994-1004.
  65. Mazza F, Tronconi E, Valerio A, Groettrup M, Kremer M, Tossi A, Benedetti F, Cargnel A, Atzori C. 2006. The non-peptidic HIV protease inhibitor Tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate pneumocystis carinii growth and proteasome activity of HEL299 cell line. J Eukaryot Microbiol 53:S144–S146.
  66. Basler M, Groettrup M. 2007. Advances in prostate cancer immunotherapies. Drugs Aging 24(3):197-221.
  67. Basler M, Groettrup M. 2007. No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes. Eur J Immunol 37(4):896-904.
  68. Pelzer C, Kassner I, Matentzoglu K, Singh RK, Wollscheid HP, Scheffner M, Schmidtke G, Groettrup M. 2007. UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem 282(32):23010-23014.
  69. Krause P, Singer E, Darley PI, Klebensberger J, Groettrup M, Legler DF. 2007. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leuk Biol 82(5):1106-1114.
  70. Schlosser E, Otero C, Wünsch C, Kessler BM, Edelmann M, Brunisholz R, Drexler I, Legler DF*, Groettrup M*. 2007. A novel cytosolic class I antigen-processing pathway for endoplasmic-reticulum-targeted proteins. EMBO Rep 8(10):945-951. * share senior authorship
  71. Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, Groettrup M. 2008. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26(13):1626-1637.
  72. Groettrup M, Pelzer C, Schmidtke G, Hofmann K. 2008. Activating the ubiquitin family: UBA6 challenges the field. Trends Biochem Sci 33(5):230-237.
  73. Otero C, Eisele PS, Schaeuble K, Groettrup M, Legler DF. 2008. Distinct motifs in the chemokine receptor CCR7 regulate signal transduction, receptor trafficking and chemotaxis. J Cell Sci 121(16):2759-2767.
  74. Lukasiak S, Breuhahn K, Schiller C, Schmidtke G, Groettrup M. 2008. Quantitative analysis of gene expression relative to 18S rRNA in carcinoma samples using the LightCycler instrument and a SYBR GreenI-based assay: determining FAT10 mRNA levels in hepatocellular carcinoma. Meth Mol Biol 429:59-72.
  75. Schmidtke G, Groettrup M. 2008. Identification of homozygous transgenic mice by genomic real-time PCR. Meth Mol Biol 429:45-58.
  76. Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K, Groettrup M. 2008. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 27(46):6068-6074.
  77. Kalveram B, Schmidtke G, Groettrup M. 2008. The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. J Cell Sci 121(24):4079-4088.
  78. Krause P, Bruckner M, Uermoesi C, Singer C, Groettrup M, Legler DF. 2009. Prostaglandin E2 enhances T cell proliferation by inducing the costimulatory molecules OX40L, CD70 and 4-1BBL on dendritic cells. Blood 113(11):2451-2460.
  79. Schmidtke G, Kalveram B, Groettrup M. 2009. Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L. FEBS Lett 583(3):591-594.
  80. Fischer S, Schlosser E, Mueller M, Csaba N, Merkle HP, Groettrup M, Gander B. 2009. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target 17(8):652-661.
  81. Muchamuel T*, Basler M*, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, Groettrup M. 2009. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15(7):781-787. * shared first authorship
  82. Basler M, Lauer C, Beck U, Groettrup M. 2009. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 183(10):6145-6150.
  83. Sommershof A, Aichinger H, Engler H, Adenauer H, Catani C, Boneberg EM, Elbert T, Groettrup M, Kolassa IT. 2009. Substantial reduction of naïve and regulatory T cells following traumatic stress. Brain Behav Immun 23(8):1117-1124.
  84. Groettrup M, Kirk CJ, Basler M. 2010. Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 10(1):73-78.
  85. Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M. 2010. The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 128(2):473-81.
  86. Aichem A, Pelzer C, Lukasiak S, Kalveram B, Sheppard PW, Rani N, Schmidtke G, Groettrup M. 2010. USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10 which FAT10ylates itself in cis. Nat Commun 1(2):1-10.
  87. Basler M, Dajee M, Moll C, Groettrup M, Kirk CJ. 2010. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome1. J Immunol 185(1):634-641.
  88. Kremer M, Henn A, Kolb C, Basler M, Moebius J, Guillaume B, Leist M, Van Den Eynde BJ, Groettrup M. 2010. Reduced immunoproteasome formation and accumulation of immunoproteasomal percursors in the brain of lymphocytic choriomeningitis virus-infected mice. J Immunol 185(9):5549-5560.
  89. Moebius J, Van den Broek M, Groettrup M, Basler M. 2010. Immunoproteasomes are essential for survival and expansion of T cells in virus infected mice. Eur J Immunol 40(12):3439-3449.
  90. Sommershof A, Basler M, Riether C, Engler H, Groettrup M. 2010. Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress. Brain Behav Immun in press
  91. Mueller M, Schlosser E, Gander B, Groettrup M. 2010. Tumor eradication by immunotherapy with biodegradable PLGA microspheres - an alternative to incomplete Freund´s adjuvant. Int J Cancer in press
  92. Schliehe C, Schliehe C, Thiry M, Tromsdorf UI, Hentschel J, Weller H, Groettrup M. 2011. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. J Controlled Release 151(3):278-85.
  93. Schliehe C, Redaelli C, Engelhardt S, Fehlings M, Mueller M, van Rooijen N, Thiry M, Hildner K, Weller H, Groettrup M. 2011. CD8- dendritic cells and macrophages cross-present PLGA microsphere-encapsulated antigen in vivo. J Immunol in press
  94. Schaeuble K, Hauser MA, Singer E, Groettrup M, Legler DF. 2011. Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. J Immunol 187(11):5645-52.
  95. Basler M, Moebius J, Beck U, Kirk CC, Groettrup M. 2011. Analysis of mice deficient for all catalytically active immunoproteasome subunits. J Immunol in press
  96. Spies E, Reichardt W, Alvarez G, Groettrup M, Oehlschlaeger P. 2011. DNA electroporation of an artificial prostate acid phosphatase gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. Mol Ther in press

 BITg

Biotechnologie Institut Thurgau
an der Universität Konstanz
Unterseestrasse 47
CH-8280 Kreuzlingen
Schweiz
Fon +41 (0)71 678 5020
Fax +41  (0)71 678 5021
 DNA_BITg

© 2010.     Nach oben